The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse

Psychopharmacology

Volumn 231, Issue 23, 2014, Pages 4527-4540

  Jacobsen, Jacob P R ^a   Plenge, Per ^b   Sachs, Benjamin D ^a   Pehrson, Alan L ^c   Cajina, Manuel ^c   Du, Yunzhi ^a   Roberts, Wendy ^a   Rudder, Meghan L ^a   Dalvi, Prachiti ^a   Robinson, Taylor J ^a   O'Neill, Sharon P ^d   Khoo, King S ^d   Morillo, Connie Sanchez ^c   Zhang, Xiaodong ^d   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUNDBECK RESEARCH USA   (United States)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

5 HT; Allosteric; Antidepressant; Escitalopram; Microdialysis; R citalopram

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; ANIMAL BEHAVIOR; BINDING SITE; BRAIN; DRUG EFFECTS; DRUG INTERACTION; GENETICS; IMMOBILIZATION; MALE; METABOLISM; MICRODIALYSIS; MOUSE; TRANSGENIC MOUSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BINDING SITES; BRAIN; CITALOPRAM; DRUG INTERACTIONS; HINDLIMB SUSPENSION; MALE; MICE; MICE, TRANSGENIC; MICRODIALYSIS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84939883816     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3595-1     Document Type: Article

References (91)

1. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ (2012) Ketamine for depression: where do we go from here? Biol Psychiatry 72:537-547
2. Artigas F, Romero L, de Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19:378-383
3. Barker EL, Kimmel HL, Blakely RD (1994) Chimeric human and rat serotonin transporters reveal domains involved in recognition of transporter ligands. Mol Pharmacol 46:799-807
4. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR, Caron MG (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A 105:1333-1338
5. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T (2008) A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165:617-620
6. Blakely RD, Berson HE, Fremeau RT Jr, Caron MG, Peek MM, Prince HK, Bradley CC (1991) Cloning and expression of a functional serotonin transporter from rat brain. Nature 354:66-70
7. Blier P (2003) The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13:57-66
8. Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163:121-141
9. Brosen K, Naranjo CA (2001) Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 11:275-283
10. Bunin MA, Wightman RM (1998) Quantitative evaluation of 5-hydroxytryptamine (serotonin) neuronal release and uptake: an investigation of extrasynaptic transmission. J Neurosci 18:4854-4860
11. Cervo L, Canetta A, Calcagno E, Burbassi S, Sacchetti G, Caccia S, Fracasso C, Albani D, Forloni G, Invernizzi RW (2005) Genotype-dependent activity of tryptophan hydroxylase-2 determines the response to citalopram in a mouse model of depression. J Neurosci 25:8165-8172
12. Chang AS, Chang SM, Starnes DM, Schroeter S, Bauman AL, Blakely RD (1996) Cloning and expression of the mouse serotonin transporter. Brain Res Mol Brain Res 43:185-192
13. Chen F, Larsen MB, Sanchez C, Wiborg O (2005) The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 15:193-198
14. Colonna L, Andersen HF, Reines EH (2005) A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 21:1659-1668
15. Cristalli G, Lambertucci C, Marucci G, Volpini R, Dal Ben D (2008) A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists. Curr Pharm Des 14:1525-1552
16. Crowley JJ, Blendy JA, Lucki I (2005) Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology 183:257-264
17. Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR, Page ME, Dalvi A, Thomas SA, Lucki I (2004) Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc Natl Acad Sci U S A 101:8186-8191
18. Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571-625
19. David DJ, Renard CE, Jolliet P, Hascoet M, Bourin M (2003) Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology 166:373-382
20. de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ (2010) Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9:628-642
21. Deacon RM (2006) Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc 1:122-124
22. DeFelipe J, Jones EG (1988) A light and electron microscopic study of serotonin-immunoreactive fibers and terminals in the monkey sensory-motor cortex. Exp Brain Res 71:171-182
23. Descarries L, Riad M (2012) Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Philos Trans R Soc Lond B Biol Sci 367:2416-2425
24. Descarries L, Audet MA, Doucet G, Garcia S, Oleskevich S, Seguela P, Soghomonian JJ, Watkins KC (1990) Morphology of central serotonin neurons. Brief review of quantified aspects of their distribution and ultrastructural relationships. Ann N Y Acad Sci 600:81-92
25. Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, Kerekes MF, Gerken M, Wieseler B (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341:c4737
26. Fish EW, Faccidomo S, Gupta S, Miczek KA (2004) Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups. J Pharmacol Exp Ther 308:474-480
27. Fox MA, Jensen CL, French HT, Stein AR, Huang SJ, Tolliver TJ, Murphy DL (2008) Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. Psychopharmacology 201:203-218
28. Franklin K, Paxinos G (1997) The mouse brain in stereotaxic coordinates. Academic Press, San Diego
29. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ (2012) Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 69:572-579
30. Gitter BD, Waters DC, Bruns RF, Mason NR, Nixon JA, Howbert JJ (1991) Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol 197:237-238
31. Griebel G, Beeske S, Stahl SM (2012) The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 73:1403-1411
32. Harmer CJ, Goodwin GM, Cowen PJ (2009) Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 195:102-108
33. Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, Hashimoto H, Yamada S (2005) Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 144:695-702
34. Hjorth S, Westlin D, Bengtsson HJ (1997) WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology 36:461-465
35. Ireland-Denny L, Parihar AS, Miller TR, Kang CH, Krueger KM, Esbenshade TA, Hancock AA (2001) Species-related pharmacological heterogeneity of histamine H(3) receptors. Eur J Pharmacol 433:141-150
36. Iyengar S, Hipskind PA, Gehlert DR, Schober D, Lobb KL, Nixon JA, Helton DR, Kallman MJ, Boucher S, Couture R, Li DL, Simmons RM (1997) LY303870, a centrally active neurokinin-1 antagonist with a long duration of action. J Pharmacol Exp Ther 280:774-785
37. Jacobsen JP, Nielsen EO, Hummel R, Redrobe JP, Mirza N, Weikop P (2008) Insensitivity of NMRI mice to selective serotonin reuptake inhibitors in the tail suspension test can be reversed by co-treatment with 5-hydroxytryptophan. Psychopharmacology 199:137-150
38. Jacobsen JP, Medvedev IO, Caron MG (2012a) The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouse. Philos Trans R Soc Lond B Biol Sci 367:2444-2459
39. Jacobsen JP, Siesser WB, Sachs BD, Peterson S, Cools MJ, Setola V, Folgering JH, Flik G, Caron MG (2012b) Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice. Mol Psychiatry 17:694-704
40. Jennings KA, Loder MK, Sheward WJ, Pei Q, Deacon RM, Benson MA, Olverman HJ, Hastie ND, Harmar AJ, Shen S, Sharp T (2006) Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J Neurosci 26:8955-8964
41. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S (2006) Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59:216-223
42. Kennedy SH, Andersen HF, Lam RW (2006) Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 31:122-131
43. Kittler K, Lau T, Schloss P (2010) Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur J Pharmacol 629:63-67
44. 123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology 188:263-272
45. Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, Lanzenberger R, Spindelegger C, Holik A, Asenbaum S, Dudczak R, Tauscher J, Kasper S (2007) Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology 191:333-339
46. Kobayashi T, Hayashi E, Shimamura M, Kinoshita M, Murphy NP (2008) Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology 197:567-580
47. Kreilgaard M, Smith DG, Brennum LT, Sanchez C (2008) Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice. Br J Pharmacol 155:276-284
48. Leffler A, Ahlstedt I, Engberg S, Svensson A, Billger M, Oberg L, Bjursell MK, Lindstrom E, von Mentzer B (2009) Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol 77:1522-1530
49. Lepola UM, Loft H, Reines EH (2003) Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18:211-217
50. Lepola U, Wade A, Andersen HF (2004) Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 19:149-155
51. Llorca PM, Azorin JM, Despiegel N, Verpillat P (2005) Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 59:268-275
52. Lucas G, Rymar VV, Sadikot AF, Debonnel G (2008) Further evidence for an antidepressant potential of the selective sigma1 agonist SA 4503: electrophysiological, morphological and behavioural studies. Int J Neuropsychopharmacol 11:485-495
53. Lundberg J, Christophersen JS, Petersen KB, Loft H, Halldin C, Farde L (2007) PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int J Neuropsychopharmacol 10:777-785
54. Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G (2012) Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. J Neuroendocrinol 24:609-628
55. Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sanchez C, Haddjeri N (2007) Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int J Neuropsychopharmacol 10:31-40
56. Maurice T, Su TP (2009) The pharmacology of sigma-1 receptors. Pharmacol Ther 124:195-206
57. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161:826-835
58. Michelson D, Adler LA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF, Kelsey DK, Williams DW (2007) Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:582-587
59. Moore N, Verdoux H, Fantino B (2005) Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20:131-137
60. Mork A, Kreilgaard M, Sanchez C (2003) The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45:167-173
61. Neubauer HA, Hansen CG, Wiborg O (2006) Dissection of an allosteric mechanism on the serotonin transporter: a cross-species study. Mol Pharmacol 69:1242-1250
62. Neurocrine (2013) Corticotropin-releasing factor (CRF) antagonist. http://phx.corporate-ir.net/phoenix.zhtml?c=68817&p=irol-newsArticle&ID=1471129&highlight=. Accessed 5 May 2014
63. Nguyen HT, Guiard BP, Bacq A, David DJ, David I, Quesseveur G, Gautron S, Sanchez C, Gardier AM (2012) Blockade of the high-affinity norepinephrine transporter (NET) by the selective serotonin reuptake inhibitor escitalopram: an in vivo microdialysis study in mice. Br J Pharmacol 168:103-16
64. Nikisch G, Mathe AA, Czernik A, Thiele J, Bohner J, Eap CB, Agren H, Baumann P (2005) Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response. Psychopharmacology 181:751-760
65. Njung'e K, Handley SL (1991) Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 104:105-112
66. Owens MJ, Knight DL, Nemeroff CB (2001) Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350
67. 3H-imipramine. Prog Neuro-Psychopharmacol Biol Psychiatry 14:61-72
68. Plenge P, Gether U, Rasmussen SG (2007) Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites. Eur J Pharmacol 567:1-9
69. Plenge P, Shi L, Beuming T, Te J, Newman AH, Weinstein H, Gether U, Loland CJ (2012) Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporter. J Biol Chem 287:39316-39326
70. Preti A (2002) Tomoxetine (Eli Lilly & Co). Curr Opin Investig Drugs 3:272-277
71. PsychCentral (2009) PsychCentral. http://psychcentral.com/lib/top-25-psychiatric-prescriptions-for-2009/0003170. Accessed 5 May 2014
72. Ramamoorthy S, Blakely RD (1999) Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science 285:763-766
73. Ramamoorthy S, Shippenberg TS, Jayanthi LD (2011) Regulation of monoamine transporters: Role of transporter phosphorylation. Pharmacol Ther 129:220-238
74. Rao N (2007) The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 46:281-290
75. Rossi DV, Burke TF, Hensler JG (2008a) Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram. Eur J Pharmacol 583:103-107
76. Rossi DV, Burke TF, McCasland M, Hensler JG (2008b) Serotonin-1A receptor function in the dorsal raphe nucleus following chronic administration of the selective serotonin reuptake inhibitor sertraline. J Neurochem 105:1091-1099
77. Sanchez C (2006) The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 99:91-95
78. Sanchez C, Kreilgaard M (2004) R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 77:391-398
79. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O (2003a) Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 167:353-362
80. Sanchez C, Gruca P, Papp M (2003b) R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 14:465-470
81. Savelieva KV, Zhao S, Pogorelov VM, Rajan I, Yang Q, Cullinan E, Lanthorn TH (2008) Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants. PLoS ONE 3:e3301
82. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997) Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9:686-692
83. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA (2013) Serotonergic drugs for depression and beyond. Curr Drug Targets 14:578-585
84. Steru L, Chermat R, Thierry B, Simon P (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85:367-370
85. Storustovu S, Sanchez C, Porzgen P, Brennum LT, Larsen AK, Pulis M, Ebert B (2004) R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 142:172-180
86. Sur C, Betz H, Schloss P (1997) A single serine residue controls the cation dependence of substrate transport by the rat serotonin transporter. Proc Natl Acad Sci U S A 94:7639-7644
87. Thase ME (2006) Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci 8:217-226
88. Thompson BJ, Jessen T, Henry LK, Field JR, Gamble KL, Gresch PJ, Carneiro AM, Horton RE, Chisnell PJ, Belova Y, McMahon DG, Daws LC, Blakely RD (2011) Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter. Proc Natl Acad Sci U S A 108:3785-3790
89. Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV (2007) Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther 29:2319-2332
90. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C (2009) An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett 462:207-212
91. Zhong H, Haddjeri N, Sanchez C (2011) Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter - a review of current understanding of its mechanism of action. Psychopharmacology 219:1-13